In our previous study, we found that the PD-1 inhibitor (Nivolumab) affects HSP90 expression in peripheral blood and bone marrow lymphocytes in refractory or recurrent Hodgkin’s lymphoma patients [40]. Here, HSP90AB1 is linked to Hodgkins lymphoma.